Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PER Pulse™ Recaps
The Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian Cancer CME-certified satellite symposium was held adjunct to the 47th Society of Gynecologic Oncology (SGO) Annual Meeting on March 19, 2016, in San Diego, California. This symposium brought together top experts in the field of ovarian cancer to review the biologic rationale and available clinical data regarding the efficacy and safety of PARP inhibitors in advanced ovarian cancer, and to discuss both investigational directions and practical strategies for integrating these agents into clinical practice.
This activity is supported by an educational grant from Clovis Oncology; Foundation Medicine, Inc; and Myriad Genetics, Inc.
This activity focuses on management strategies in ovarian cancer and features a series of short video interviews with leading experts in the treatment of ovarian cancer. The content and interviews are based on presentations given at Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian Cancer, a CME-certified, ancillary satellite symposium held at the Annual Meeting on Women’s Cancer®.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists who treat patients with ovarian cancer. Obstetrician/gynecologists, nurses, physician assistants, fellows, residents, and other healthcare professionals interested in the treatment of ovarian cancer may also participate.
Michael J. Birrer, MD, PhD
Professor of Medicine, Harvard Medical School
Director, Gillette Center for Gynecologic Oncology
Massachusetts General Hospital
Disclosure: No relevant financial relationships with commercial interests.
Maurie Markman, MD
President, CTCA Medicine and Science
Cancer Treatment Centers of America
Disclosure: Consultant: Amgen, Celgene, CritiTech; Speaker's Bureau: Genentech, AstraZeneca.
Joyce Liu, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Physician, Dana-Farber Cancer Institute
Disclosure: Consultant: AstraZeneca; Investigational/Off-Label Use of Drugs or Device: Olaparib, Veliparib, Niraparib, Rucaparib, Talazoparib.
James Tate Thigpen, MD
Professor of Medicine
Director, Division of Hematology and Oncology
The University of Mississippi Medical Center
Disclosure: Speaker's Bureau: Amgen, Boehringer Ingelheim, Genentech, Janssen Biotech, AstraZeneca, Lilly.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests.
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY